Cargando…

A Retrospective Study on Erythropoiesis Stimulating Agent Dose Reducing Potential of an Anti‐Platelet Activation Membrane Dialyzer in Hemodialysis Patients

Our previous small‐scale trial demonstrated an erythropoiesis stimulating agent (ESA)‐sparing potential of the TORAYLIGHT NV (NV) dialyzer in hemodialysis patients with high interleukin‐6 levels. We now retrospectively explored this ESA‐sparing potential of the NV dialyzer in 122 and 129 prevalent d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kakuta, Takatoshi, Ishida, Mari, Komaba, Hirotaka, Suzuki, Hajime, Fukagawa, Masafumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379541/ https://www.ncbi.nlm.nih.gov/pubmed/30311350 http://dx.doi.org/10.1111/1744-9987.12759

Ejemplares similares

Regulation of platelet count by erythropoiesis-stimulating agents – iron axis in hemodialysis patients
por: Koike, Kiyomi, et al.
Publicado: (2016)

Evaluation of ABCG2-mediated extra-renal urate excretion in hemodialysis patients
por: Ohashi, Yuki, et al.
Publicado: (2023)

Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review
por: Komaba, Hirotaka, et al.
Publicado: (2008)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

Parathyroid hormone-producing cells exist in adipose tissues surrounding the parathyroid glands in hemodialysis patients with secondary hyperparathyroidism
por: Kakuta, Takatoshi, et al.
Publicado: (2020)

The effect of altitude on erythropoiesis-stimulating agent dose, hemoglobin level, and mortality in hemodialysis patients
por: Sibbel, Scott, et al.
Publicado: (2016)

Selenium Associates With Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Yasukawa, Minoru, et al.
Publicado: (2022)

Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Lee, Yu-Ting, et al.
Publicado: (2022)

Medium cut-off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin-independent manner in maintenance hemodialysis patients: results from a randomized controlled trial
por: Lim, Jeong-Hoon, et al.
Publicado: (2020)

Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
por: Suttorp, Marit M, et al.
Publicado: (2013)

Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

En Bloc Cadaver Kidney Transplantation From a 9-Month-Old Donor to an Adult Recipient: Maturation of Glomerular Size and Podocyte in the Recipient
por: Hirukawa, Takashi, et al.
Publicado: (2017)

Changes in Fibroblast Growth Factor 23 and Soluble Klotho Levels After Hemodialysis Initiation
por: Kawabata, Chiaki, et al.
Publicado: (2019)

Resistance to Erythropoiesis-Stimulating Agents Is Associated with Arterial Microcalcification in Early Hemodialysis Patients
por: Won, Hye Sung, et al.
Publicado: (2014)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial
por: Saglimbene, Valeria, et al.
Publicado: (2017)

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2016)

Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention
por: Goto, Shunsuke, et al.
Publicado: (2008)

Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine
por: Komaba, Hirotaka, et al.
Publicado: (2021)

Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients
por: Nguyen, Timothy V., et al.
Publicado: (2011)

Responsiveness to an erythropoiesis-stimulating agent is correlated with body composition in patients undergoing chronic hemodialysis
por: Lee, Hyang Yun, et al.
Publicado: (2022)

Response to Letter to the Editor From Sumi et al: “Lower Bone Turnover and Skeletal PTH Responsiveness in Japanese Compared to European Patients Receiving Hemodialysis”
por: Jørgensen, Hanne Skou, et al.
Publicado: (2022)

Vitamin e-loaded membrane dialyzers reduce hemodialysis inflammaging
por: Sepe, Vincenzo, et al.
Publicado: (2019)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014)

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents
por: Haase, Volker H, et al.
Publicado: (2019)

Serum trace metal association with response to erythropoiesis stimulating agents in incident and prevalent hemodialysis patients
por: Brier, Michael E., et al.
Publicado: (2020)

Erythropoiesis stimulating agents are associated with serum fibroblast growth factor 23 metabolism in patients on hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2020)

Comparison of Patient Survival According to Erythropoiesis-Stimulating Agent Type of Treatment in Maintenance Hemodialysis Patients
por: Kang, Seok Hui, et al.
Publicado: (2023)

Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder
por: Goto, Shunsuke, et al.
Publicado: (2013)

Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen
por: Stefánsson, Bergur V., et al.
Publicado: (2011)

Ensuring hemodialysis adequacy by dialysis dose monitoring with UV spectroscopy analysis of spent dialyzate
por: Zhang, Li, et al.
Publicado: (2021)

Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents
por: van der Weerd, Neelke C., et al.
Publicado: (2012)

The Resection of Thyroid Cancer Was Associated with the Resolution of Hyporesponsiveness to an Erythropoiesis-stimulating Agent in a Hemodialysis Patient with Aceruloplasminemia
por: Nagata, Soichiro, et al.
Publicado: (2017)

Serum total indoxyl sulfate and clinical outcomes in hemodialysis patients: results from the Japan Dialysis Outcomes and Practice Patterns Study
por: Yamamoto, Suguru, et al.
Publicado: (2020)

Erythropoiesis stimulating agents: approaches to modulate activity
por: Sinclair, Angus M
Publicado: (2013)

Altitude Pre-Acclimatization with an Erythropoiesis-Stimulating Agent
por: Heldeweg, Micah L. A., et al.
Publicado: (2023)

Performance of hemodialysis with novel medium cut-off dialyzers
por: Kirsch, Alexander H., et al.
Publicado: (2017)

Clinical and microbiological effects of dialyzers reuse in hemodialysis patients
por: Ribeiro, Isabella Carvalho, et al.
Publicado: (2019)

High-performance dialyzers and mortality in maintenance hemodialysis patients
por: Abe, Masanori, et al.
Publicado: (2021)

Should We Use Dialyzable β-Blockers in Hemodialysis?
por: Georgianos, Panagiotis I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_73tcffli2ig5dsc77bjh2otghn